The UK’s Churchill Hospital Oxford included a 70-year-old male that was diagnosed with mesothelioma  of the lung. He was given a year to live at most, according to Karolina Kaminska writing for Express.  Professor Angus Dalgleish included the patient in an immunotherapy drug known as IMM-101.  The patient received injections every four to six months in addition to regular scans. Ms. Kaminska notes that the study was funded by the nonprofit  Institute for Cancer Vaccines and Immunotherapy. Six years later, the Express reports the patient’s cancer is gone.  If readers are interested, TrialSite News can do a follow up story on the Professor Dalgleish and the Institute involved.

Lead Research/Investigator

Professor Angus Dalgleish


Pin It on Pinterest